Results 131 to 140 of about 76,403 (315)

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner   +7 more
wiley   +1 more source

Deregulated enhancer‐promoter communication in cancer through altered nuclear architecture

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Enhancers are critical regulators of gene expression. Structural variations in cancer genomes can lead to enhancer hijacking, where oncogenes are activated by mistargeted enhancer activity. Novel enhancer‐promoter interactions may also arise through chromosomal rearrangements that create extrachromosomal DNA elements.
Isabelle Seufert   +3 more
wiley   +1 more source

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities

open access: yesInternational Journal of Cancer, EarlyView.
Abstract In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly.
Subhasree Kumar   +2 more
wiley   +1 more source

A promising frontier of circulating messenger RNA in liquid biopsy: From mechanisms to clinical applications

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Liquid biopsy can revolutionize cancer patient management as repeated sampling allows real‐time monitoring of disease progression and response to treatment. The circulating transcriptome represents a rich source of potential cancer biomarkers, including coding and non‐coding RNAs.
Mengqian Li   +7 more
wiley   +1 more source

CD86, the double agent: Significance of CD86 expression in B‐cell malignancies

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Bypassing the anti‐tumor functions of the immune system is one of the keys to tumor survival. Tumors, especially hematological tumors, produce or express factors that retune T and B cells to inhibit the immune response. Coreceptors CD28 and CTLA‐4, and their ligands, CD80 and CD86, are involved in the immunological synapse and play an ...
Gábor Barna   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy